Directed share issue in Ultimovacs ASA (NO) — NOK 270 million

Carnegie acted as joint bookrunner in the directed share issue of 2,160,000 new shares at a subscription price of NOK 125 per share. Ultimovacs is developing immune-stimulatory vaccines to treat a broad range of cancers. Ultimovacs’ lead universal cancer vaccine candidate UV1 targets human telomerase (hTERT), present in 85-90% of cancers in all stages of tumor growth.
October 2021.